An EU Logo for Safer Online Shopping for Medicines
Client Alert | 3 min read | 08.27.15
As of July 1, 2015, all internet sites that sell medicines to the public in the EU Member States (plus Norway, Iceland, and Lichtenstein) have to display a common logo established by the EU Commission.
The common logo allows the general public to easily and quickly verify that an online seller is a legal registered pharmacy or retailer by clicking on the logo, which redirects the shopper to the registration listings on the official website of the governing authorities of the EU Member States. This registration and verification process is intended to diminish the risk that consumers will purchase fraudulent or fake medicines online.
Origin of the common logo
To reduce the threat to public health and safety associated with the online sale of fraudulent and fake medicines, the EU Commission introduced the concept of a common logo that would be recognizable throughout the EU and would identify legal, registered online pharmacies and retailers in Directive 2011/62/EU of June 8, 2011. That Directive amended Directive 2001/83/EC, which addresses medicinal products for human use and prevents the entry into commerce of falsified medicinal products (the "Falsified Medicines Directive").
In Implementing Regulation 699/2014 of June 24, 2014 (Implementing Regulation), the EU Commission used the power granted by the Falsified Medicines Directive to i) develop and adopt a new common logo for identifying persons authorized to sell medicines online, and ii) to specify the technical, electronic, and cryptographic requirements to verify the authenticity of that common logo.
The Implementing Regulation granted Member States approximately one year to introduce the common logo into their national legislation.
This transition period ended on June 30, 2015. As of July 1, 2015, the EU common logo must appear on every website page that offers medicines for sale to the public in the EU, including every page of third-party websites that offer a marketplace for online sales of medicines.
Look and feel of the common logo
As shown in the example for Belgium, below, the left-hand side of the EU common logo is the national flag of the EU Member State where the online supplier is established. Next to the flag, the phrase "Click to verify if the website is operating legally" appears in the language of the EU Member State where the online supplier is established and links to the official registration page for online pharmacies and retailers who have been authorized to sell medicines by the national governing authority. In addition, the Implementing Regulation requires the EU common logo to be static, to have a minimum width of 90 pixels, and to use specific reference colors.
For Belgium the common logo will look as follows:
Other Articles in This Month's Edition:
- Third Circuit Upholds the FTC’s Authority to Regulate 'Unfair' Data Security Practices
- Senator Markey Introduces the SPY Car Act to Regulate Automotive Cybersecurity
- FDA Loses Battle to Limit Truthful, Non-Misleading Off-Label Promotion of Approved Drugs
- A Hashtag Away from a Warning Letter? Kim Kardashian's Instagram Post Triggers FDA Warning Letter that Sends a Strong Message to Drug Makers
- Got Lead? Significant Changes to Proposition 65's Lead MADL May Be on the Horizon
- Advertisers in the Ring – A Roundup of This Month's Competitor Advertising Challenges: Unique Features and Outstanding Reviews – What Counts?
Contacts
Insights
Client Alert | 5 min read | 12.12.25
Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality
On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument.
Client Alert | 8 min read | 12.11.25
Director Squires Revamps the Workings of the U.S. Patent Office
Client Alert | 8 min read | 12.10.25
Creativity You Can Use: CJEU Clarifies Copyright for Applied Art
Client Alert | 4 min read | 12.10.25
Federal Court Strikes Down Interior Order Suspending Wind Energy Development
